Official Title of the study:
A Randomized Controlled Trial with Rituximab for Psychotic Disorder in Adults (RCT-RITS)

NCT05622201

The 3.1 version of the study protocol was approved by the Ethical committee, Stockholm, Sweden on the 30th of August 2023 and by the Swedish medical product agency on the 8th of August 2023.

Consent to participate in the study

I have received oral and written information about the study and have had the opportunity to ask questions. I get to keep the written information.

	Yes	No
• I agree to participate in the study RCT-RITS, Rituximab – a placebo-controlled study for psychosis Meaning: a. I consent to data about me being processed in the manner described in the research subject information. b. I agree that the study monitor have access to medical records for checking the data. c. I agree that the research group have access to my data.	☐	☐

	Yes	No
• I agree to provide samples of spinal fluid through lumbar puncture and that these are saved in the biobank.	☐	☐
• I agree to blood samples being taken and stored in a biobank in the manner described in the research subject information.	☐	☐
• I agree to undergo MRI examination in the manner described in the research subject information.	☐	☐
• I agree that relatives or other persons who know me well can be interviewed about my state of health and fill out a questionnaire after I receive the treatment.	☐	☐
• I agree to be interviewed about my experiences of the study after treatment and answer a short questionnaire.	☐	☐

…….. ……..
Location Date

…… ……
Study participant's signature Responsible study physician

…… ……
Texted name Texted name